Centre du Cancer Lausanne




Home < Centre de recherche < Publications 2010 < Publications 2010

	Publications 2010

Publications 2009

Publications 2008

Publications 2007

Publications 2006

Publications 2005

Publications 2004

Publications 2003

Publications 2002

Publications 2001

Info.onco@chuv.ch

Publications

Etudes cliniques d’oncologie médicale réalisées par le CePO avec ses partenaires:

2010
1:	Aapro M.S., Leyvraz S., Sappino A.P.
		Oncologie médicale: la renaissance revisitée... [Medical oncology: the Renaissance revisited...]. Revue Médicale Suisse 6(250), 1043.
2:	Advani A., Coiffier B. Czuczman Myron S., Dreyling M., Foran J., Gine E., Gisselbrecht C., Ketterer N., Nasta S., Rohatiner A. Schmidt-Wolf I., Schuler M., Sierra J., Smith M. Verhoef G., Winter J.N., Boni J., Vandendries E., Shapiro M., Fayad L.,
		Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of Clinical Oncology 28(12), 2085-2093.
3:	Azria D., Belkacemi Y., Romieu G., Gourgou S., Gutowski M., Zaman K., Moscardo C. Llacer, Lemanski C., Coelho M., Rosenstein B., Fenoglietto P., Crompton N., Ozsahin M
		Azria D., Belkacemi Y., Romieu G., Gourgou S., Gutowski M., Zaman K., Moscardo C. Llacer, Lemanski C., Coelho M., Rosenstein B., Fenoglietto P., Crompton N., Ozsahin M Lancet Oncology 11(3), 258-265.
4:	Berthod G., Bouzourene H., Pachinger C., Peters S.
		Solitary choriocarcinoma in the lung. Journal of Thoracic Oncology 5(4), 574-575 Journal of Thoracic Oncology 5(4), 574-575
5:	Berthold D.
		Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology 21(3), 665; author reply 655-665; author reply 656.
6:	Bizzini A., Entenza J.M., Michielin O., Arnold I., Erni B., Moreillon P.
		A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii. Antimicrobial Agents and Chemotherapy 54(1), 259-266.
7:	Bolla M., Hannoun-Levi J.M., Ferrero J.M., Maingon P., Buffet-Miny J., Bougnoux A., Bauer J., Descotes J.L., Fourneret P., Jover F., Colonna M.,
		Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology 97(2), 312-317.
8:	Caballero O.L., Zhao Q., Rimoldi D., Stevenson B.J., Svobodová S., Devalle S., Röhrig U.F., Pagotto A., Michielin O., Speiser D., Wolchok J.D., Liu C., Pejovic T., Odunsi K., Brasseur F., Van den Eynde B.J., Old L.J., Lu X., Cebon J., Strausberg R.L., Simpson A.J.
		Frequent MAGE Mutations in Human Melanoma Plos One 5(11).
9:	Cellerai C., Perreau M., Rozot V., Enders F.B., Pantaleo G., Harari A.
		Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression. Journal of Virology 84(8), 3868-3878
10:	Cheng C., Debefve E., Haouala A., Andrejevic-Blant S., Krueger T., Ballini J., Peters S., Decosterd L., van den Bergh H., Wagnieres G., Perentes J.., Ris H.-B
		Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs. Lasers in Surgery and Medicine 42(5), 391-399.
11:	Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Rüegg C.
		Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol. 30(6):529- 536
12:	Cicone F., Russo E., Carpaneto A., Prior J.O., Delaloye A.B., Scopinaro F., Ketterer N.
		Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after (90)Y-ibritumomab-tiuxetan. Hematological Oncology , 100.
13:	Dahmane E., Mercier T., Zanolari B., Cruchon S., Guignard N., Buclin T., Leyvraz S., Zaman K., Csajka C., Decosterd L.A.
		An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences 878(32), 3402-3414.
14:	Derré L., Rivals J.P., Jandus C., Pastor S., Rimoldi D., Romero P., Michielin O., Olive D., Speiser D.E.
		BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. Journal of Clinical Investigation 120(1), 157-167.
15:	Dollinger M.M., Lautenschlaeger C., Lesske J., Tannapfel A., Wagner A.D., Schoppmeyer K., Nehls O., Welker M.W., Wiest R., Fleig W.E., AIO Hepatobiliary Study Group
		Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. Bmc Cancer 10, 457
16:	Fiche M., Lepori D., Guntern D., Jucker-Kupper P., Jeanneret W., Zaman K., Vadot S., Delaloye J.F.
		Improving breast cancer education: the case of an evolving multidisciplinary module for undergraduate medical students (Lausanne Medical School, 1993-2008). Journal of Cancer Education : the Official Journal of the American Association For Cancer Education 25(1), 101-105.
17:	Gallerani E., Bauer J., Hess D., Boehm S., Droege C., Jeckelmann S., Miani M., Herrmann R., Marsoni S., Sperka S., Sessa C.
		A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies. Acta Oncologica (stockholm, Sweden).
18:	Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D.C., Trneny M., Bosly A., Ketterer N., Shpilberg O., Hagberg H., Ma D., Brière J., Moskowitz C.H., Schmitz N.
		Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology 28(27), 4184-4190.
19:	Guillaume P, Baumgaertner P, Neff L, Rufer N, Wettstein P, Speiser DE, and Luescher IF.
		Novel soluble HLA-A2/Melan-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma. Int J Cancer. 127(4):910-23. 2010
20:	Haouala A., Widmer N., Duchosal M.A., Montemurro M., Buclin T., Decosterd L.A.
		Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood.
21:	Haouala A., Widmer N., Montemurro M., Buclin T., Decosterd L.
		Cardiovascular drug interactions with tyrosine kinase inhibitors. Cardiovascular Medicine 13(5), 147-154.
22:	Iancu, E.M., Baumgartner, P., Wieckowski, S., Speiser, D.E., and Rufer, N.
		Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T cells following therapeutic vaccination. J Biomed Biotechnol. Review.
23:	Imaizumi N., Monnier Y., Hegi M., Mirimanoff R.O., Rüegg C.
		Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting. Plos One 5(6), e11084.
24:	Kim H., Nguyen V.P., Petrova T.V., Cruz M., Alitalo K., Dumont D.J.
		Embryonic vascular endothelial cells are malleable to reprogramming via Prox1 to a lymphatic gene signature. BMC Developmental Biology 10, 72.
25:	Koeberle D., Montemurro M., Samaras P., Majno P., Simcock M., Limacher A., Lerch S., Kovacs K., Inauen R.,Hess V., Saletti P., Borner M., Roth A., Bodoky G.
		Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 15(3), 285-292.
26:	Krishnan B., Else M., Tjonnfjord G., Cazin B., Carney D., Carter J., Ketterer N., Catovsky D., Ethell M., Matutes E., Dearden C. E., 2010.
		Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. British Journal of Haematology 149(6), 907-910.
27:	Kuonen F., Touvrey C., Laurent J., Ruegg C.
		Fc block treatment, dead cells exclusion, and cell aggregates discrimination concur to prevent phenotypical artifacts in the analysis of subpopulations of tumor-infiltrating CD11b(+) myelomonocytic cells Cytometry. Part A 77(11), 1082-1090.
28:	Lüthi F., Pless M., Leyvraz S., Biedermann B., Müller E., Hermann R., Monnerat C.
		Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia Supportive Care In Cancer : Official Journal of the Multinational Association of Supportive Care In Cancer 18(12), 1515-1520.
29:	Laurent J., Speiser D.E., Appay V., Touvrey C., Vicari M., Papaioannou A., Canellini G., Rimoldi D., Rufer N., Romero P., Leyvraz S., Voelter V.
		Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. Journal of Immunotherapy (hagerstown, Md. : 1997) 33(7), 723-734.
30:	Liechti L.A., Bernèche S., Bargeton B., Iwaszkiewicz J., Roy S., Michielin O., Kellenberger S.
		A combined computational and functional approach identifies new residues involved in pH-dependent gating of ASIC1a. Journal of Biological Chemistry 285(21), 16315-16329.
31:	Ludwig H., Beksac M., Blade J., Boccadoro M., Cavenagh J., Cavo M., Dimopoulos M., Drach J., Einsele H., Facon T., Goldschmidt H., Harousseau J., Hess U. Ketterer N., Kropff M., Mendeleeva L., Morgan G., Palumbo A., Plesner T., San Miguel J., Shpilberg O. Sondergeld P., Sonneveld P., Zweegman S.
		Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 15(1), 6-25.
32:	Maillard P.V., Zoete V., Michielin O., Trono D.
		Homology-based identification of capsid determinants that protect HIV1 from human TRIM5{alpha} restriction. Journal of Biological Chemistry .
33:	Mandriota S.J., Buser R., Lesne L., Stouder C., Favaudon V., Maechler P., Béna F., Clément V., Rüegg C., Montesano R., Sappino A.P.
		Ataxia telangiectasia mutated (ATM) inhibition transforms human mammary gland epithelial cells. Journal of Biological Chemistry 285(17), 13092-13106.
34:	Martina E., Degen M., Rüegg C., Merlo A., Lino M.M., Chiquet-Ehrismann R., Brellier F.
		Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology 24(3), 778-787.
35:	Mooij P. , Balla-Jhagjhoorsingh S.S. , Beenhakker N. , van Haaften P. , Baak I. , Nieuwenhuis I.G. , Heidari S. , Wolf H. , Frachette M.J. , Bieler K. , Sheppard N. , Harari A. , Bart P.A. , Liljeström P. , Wagner R. , Pantaleo G. , Heeney J.L.
		Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens. Journal of Virology 83.
36:	Moreau P., Attal M., Pégourié B., Planche L., Hulin C., Facon T., Stoppa A.M., Fuzibet J.G., Grosbois B., Doyen C., Ketterer N., Sebban C., Kolb B., Chaleteix C., Dib M., Voillat L., Fontan J., Garderet L., Jaubert J., Mathiot C., Esseltine D., Avet-Loiseau H., Harousseau J.L.
		Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial Blood , 100.
37:	Moreau P., Hulin C., Marit G., Caillot D., Facon T., Lenain P., Berthou C., Pégourié B., Stoppa A.M., Casassus P., Michallet M., Benboubker L., Maisonneuve H., Doyen C., Leyvraz S., Mathiot C., Avet-Loiseau H., Attal M., Harousseau J.L., IFM group, 2010.
		Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 24(6), 1233-1235.
38:	Norrmén C., Vandevelde W., Ny A., Saharinen P., Gentile M., Haraldsen G., Puolakkainen P., Lukanidin E., Dewerchin M., Alitalo K., Petrova T.V.
		Liprin (beta)1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity. Blood 115(4), 906-909.
39:	Pache I., Bize P., Halkic N., Montemurro M., Giostra E., Majno P., Moradpour D.
		Prise en charge du carcinome hépatocettulaire en 2010 [Management of hepatocellular carcinoma]. Revue Médicale Suisse 6(233), 198-202.
40:	Röhrig U.F., Awad L., Grosdidier A., Larrieu P., Stroobant V., Colau D., Cerundolo V., Simpson A.J., Vogel P., Van den Eynde B.J., Zoete V., Michielin O.
		Rational design of indoleamine 2,3-dioxygenase inhibitors. Journal of Medicinal Chemistry 53(3), 1172-1189.
41:	Rüegg C., Alghisi G.C.
		Vascular Integrins: Therapeutic and Imaging Targets of Tumor Angiogenesis. pp.83-101 in Liersch R., Berdel W.E., Kessler T. (eds.) Angiogenesis Inhibition. Recent Results in Cancer Research 180. Springer
42:	Rochlitz C., Ruhstaller T., Lerch S., Spirig C., Huober J., Suter T., Bühlmann M., Fehr M., Schönenberger A., von Moos R., Winterhalder R., Rauch D., Müller A., Mannhart-Harms M., Herrmann R., Cliffe B., Mayer M., Zaman K., on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
		Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of Oncology.
43:	Schüpbach T., Zoete V., Tsakam-Sotché B., Michielin O.
		Fourier transform convolution integrals applied to generalized Born molecular volume. Journal of Computational Chemistry 31(3), 649-659.
44:	Schmid D.A., Irving M.B., Posevitz V., Hebeisen M., Posevitz-Fejfar A., Sarria J.C., Gomez-Eerland R., Thome M., Schumacher T.N., Romero P., Speiser D.E., Zoete V., Michielin O., Rufer N.
		Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. Journal of Immunology 184(9), 4936-4946.
45:	Schulte-Merker, S., Sabine, A.& Petrova T.V.
		Lymphatic vascular morphogenesis in normal development and disease. J. Cell. Biol.
46:	Shabafrouz K., Bauer J., Berthold D.R.
		Quels nouveaux médicaments a l'horizon pour te traitement du cancer avancé de la prostate [New drugs at the horizon for men with prostate cancer]. Revue Médicale Suisse 6(250), 1057-1061.
47:	Sofia Vala I, Martins LR, Imaizumi N, Nunes RJ, Rino J, Kuonen F, Carvalho LM, Rüegg C, Grillo IM, Barata JT, Mareel M, Santos SC.
		Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One. 5(6):e11222.
48:	Sturgeon J.F., Moore M.J., Kakiashvili D.M., Duran I., Anson-Cartwright L.C., Berthold D.R., Warde P.R., Gospodarowicz M.K., Alison R.E., Liu J., Ma C., Pond G.R., Jewett M.A.
		Non-Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital's Experience. Eur Urol. 2011 Apr;59(4):556-62.
49:	Tabatabai G., Weller M., Nabors B., Picard M., Reardon D., Mikkelsen T., Ruegg C., Stupp R.
		Targeting integrins in malignant glioma. Targeted Oncology 5(3), 175-181.
50:	Taverna C., Bargetzi M., Betticher D., Gmür J., Gregor M., Heim D., Hess U., Ketterer N., Lerch E., Matthes T., Mey U., Pabst T., Renner C.
		Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss Med Wkly. 2010 Sep 13;140:w13054.
51:	Vala I. Sofia, Martins L., Imaizumi N., Nunes R. J., Rino J. Kuonen F., Carvalho L., Ruegg C., Grillo I., Barata J., Mareel M., Rosa Santos S.
		Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. Plos One 5(6), 11222.
52:	Wagner A.D., Unverzagt S., Grothe W., Kleber G., Grothey A., Haerting J., Fleig W. E.
		Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 3, 004064.
53:	Wagner A.D., Zaman K., Peters S., Montemurro M., Leyvraz S.
		Traitements antiangiogéniques des cancers métastatiques du côlon et du rectum, du sein et du poumon: bénéfices et risques [Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks]. Revue Médicale Suisse 6(250), 1070-1073.
54:	Widmer N., Decosterd L.A., Csajka C., Montemurro M., Haouala A., Leyvraz S., Buclin T.
		Imatinib plasma levels: correlation with clinical benefit in GIST patients British Journal of Cancer 102(7), 1198-1199.
55:	Zaugg Longchamp D., Zaman K., Aebischer N.
		Suivi cardiologique d'un patient oncologique [Cardiologic follow up of an oncologic patient]. Revue Médicale Suisse 6(251), 1133-1139.
56:	Zoete V., Grosdidier A., Cuendet M., Michielin O.
		Use of the FACTS solvation model for protein-ligand docking calculations. Application to EADock. Journal of Molecular Recognition 23(5), 457-461.
57:	Zoete V., Irving M.B., Michielin O.
		MM-GBSA binding free energy decomposition and T cell receptor engineering. Journal of Molecular Recognition 23(2), 142-152.

Dernière modification le 05.08.2011